Moulder J E, Fish B L
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee 53226.
Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):333-7. doi: 10.1016/0360-3016(91)90115-k.
The total body irradiation that is given as part of bone marrow transplant conditioning regimens is a factor in the renal toxicity that is observed after bone marrow transplant, but it may not be the only factor. We hypothesize that nephrotoxic drugs used in prior chemotherapy can precipitate renal radiation damage. Studies were designed to determine if nephrotoxic antineoplastic drugs could shorten the latent period for the development of radiation nephritis. Rats were given bilateral renal irradiation using a radiation schedule that produced moderate nephritis. Cisplatinum, BCNU, or mitomycin were given before, during, or after irradiation at doses that produced only mild nephrotoxicity. All cisplatinum-radiation sequences resulted in decreased renal function, with radiation prior to cisplatinum producing the greatest dysfunction. BCNU increased renal dysfunction equally in all schedules, but mitomycin had only minimal effects. Most drug schedules, including those with mitomycin, produced earlier development of morbidity after fractionated renal irradiation. In a second set of studies, rats were given single doses of the same nephrotoxic drugs, followed 3 months later by total body irradiation plus bone marrow transplant. The drugs had no effect on the marrow ablation dose, but BCNU and cisplatinum decreased gastrointestinal tolerance. Four months after total body irradiation, rats which received drugs alone or total body irradiation alone have essentially normal renal function, but rats which received cisplatinum plus total body irradiation or BCNU plus total body irradiation show a dose-dependent decrease in renal function. These studies show that radiation nephritis can be precipitated by low doses of nephrotoxic drugs, and may help to explain the incidence of early radiation nephritis in bone marrow transplant patients conditioned with total body irradiation.
作为骨髓移植预处理方案一部分的全身照射是骨髓移植后观察到的肾毒性的一个因素,但它可能不是唯一的因素。我们推测先前化疗中使用的肾毒性药物会促使肾脏发生辐射损伤。本研究旨在确定肾毒性抗肿瘤药物是否会缩短放射性肾炎发生的潜伏期。采用能导致中度肾炎的照射方案对大鼠进行双侧肾脏照射。在照射前、照射期间或照射后给予顺铂、卡莫司汀或丝裂霉素,剂量仅产生轻度肾毒性。所有顺铂与辐射的联合处理均导致肾功能下降,顺铂照射前的联合处理导致的功能障碍最为严重。在所有方案中,卡莫司汀均同等程度地加重肾功能障碍,但丝裂霉素的影响最小。大多数药物处理方案,包括使用丝裂霉素的方案,在分次肾脏照射后均使发病提前。在另一组研究中,给大鼠单次给予相同的肾毒性药物,3个月后进行全身照射加骨髓移植。这些药物对骨髓清除剂量没有影响,但卡莫司汀和顺铂降低了胃肠道耐受性。全身照射4个月后,单独接受药物或单独接受全身照射的大鼠肾功能基本正常,但接受顺铂加全身照射或卡莫司汀加全身照射的大鼠肾功能呈剂量依赖性下降。这些研究表明,低剂量的肾毒性药物可促使放射性肾炎的发生,这可能有助于解释在接受全身照射预处理的骨髓移植患者中早期放射性肾炎的发生率。